WiseBeta
← Intelligence

NVO

STOCK MIXED NVO 1 research report · 0 forum mentions
Reports
1
Avg QC
83
Risk level
HIGH
Forum activity
0
Last researched
2026-05-08
+ New research
Living overview
Synthesizing overview from 1 reports...
Valuations Inflation Earnings Currency
Research timeline
Key companies & securities
NVO
Novo Nordisk A/S
Primary subject
LLY
Eli Lilly and Company
Primary competitor — tirzepatide (Mounjaro/Zepbound) franchise directly...
ETF exposure
XLV
Health Care Select Sector SPDR Fund
Broad U.S. healthcare sector ETF with pharma/biotech exposure
IHI
iShares U.S. Medical Devices ETF
Indirect exposure via pharma device overlap in GLP-1 delivery systems
ARKG
ARK Genomic Revolution ETF
Thematic exposure to metabolic and genomic medicine innovation
IXJ
iShares Global Healthcare ETF
International healthcare ETF with direct NVO ADR exposure
Knowledge graph
Nodes:
Show:
STRENGTH 0%
Hover to inspect · click to explore · scroll to zoom